Drugs / ESO-T01
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06791681 | Jan 2025 → Nov 2027 expected | refractory plasma cell neoplasm | Chunrui Li | Recruiting | No outcome recorded |
| Phase 0 | NCT06691685 | Nov 2024 → Nov 2027 expected | plasma cell myeloma | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ESO-T01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06791681 ↗ |
| Route | Intravenous | “can be administered intravenously” NCT06691685 ↗ |